NICE briefing: Overweight and obesity management
NICE guideline NG246
Published 14 January 2025; last updated 8 January 2026. This guideline combines prevention, assessment, behavioural support, medicines and surgery in a single person-centred pathway. Read NG246. NICE.
1. Start with permission, not a prescription
Ask before raising the subject of weight, and if the person declines, accept that and return to it sensitively later. Use respectful, non-stigmatising language centred on health and wellbeing and the person’s preferred terms, and take account of social, cultural, financial, medical and psychological influences. Document the conversation and the agreed next steps. NICE
2. Assess risk beyond BMI
Treat BMI as one input rather than the full picture. Adults with a BMI under 35 kg/m² should be encouraged to measure their waist-to-height ratio and seek a cardiometabolic assessment if it signals higher risk. Also consider comorbidities, ethnicity, family history, disability, neurodevelopmental needs, socioeconomic circumstances, medicines and possible eating disorders. NICE
3. The foundation is a multicomponent plan
The core approach goes beyond simply “eat less, move more”. Effective services combine dietary support, physical activity and behaviour change, set achievable staged goals, and support self-monitoring, problem-solving and maintenance. They should be respectful and non-judgemental, and aim for lasting change rather than short-term weight loss. NICE
4. Medicines are an adjunct, never a replacement
Begin and review diet, physical-activity and behavioural approaches before considering weight-management medicines, which should always accompany a reduced-calorie diet and more physical activity.
The options are tirzepatide, semaglutide, liraglutide and orlistat, but eligibility, commissioning and access vary. Semaglutide and liraglutide are generally offered through specialist weight-management services, while tirzepatide can be prescribed in primary or specialist care if eligibility and local commissioning criteria are met. NICE
5. Prescribe safely and review purposefully
Before prescribing, check eligibility, willingness to follow the behavioural plan, comorbidities, othermedicines, baseline measurements and relevant investigations. Then review effectiveness, adherence and behavioural support regularly.
Pregnancy is a contraindication to, or something to avoid with, tirzepatide, semaglutide and liraglutide. For tirzepatide, advise a non-oral contraceptive or added barrier method for four weeks after starting and after each dose increase. If weight loss is under 5% after six months at the highest tolerated dose, reassess whether continuing is justified. Support weight maintenance whenever a medicine is stopped. NICE
6. Refer earlier when complexity warrants it
Consider specialist referral for complex health needs, unsuccessful lower-intensity management, suspected eating disorder, very-low-calorie diets, surgery or specialist-only medicines. Refer for bariatric assessment ifBMI is 40 kg/m² or higher, or 35–39.9 kg/m² with a significant weight-related condition that could improve with weight loss, and the person accepts long-term follow-up. NICE
7. Practice-team actions
Make sure clinicians understand the local obesity pathway, referral criteria, capacity and the behavioural, mental-health and specialist services available. Establish consistent documentation, medicine monitoring, pregnancy and contraception checks, and clear follow-up after medicines are stopped. NICE’simplementation toolkit can support team induction and training. NICE
Remember this
- Ask permission, avoid stigma and focus on health.
- BMI is a starting point, not the whole assessment.
- Behavioural support stays the foundation, even with GLP-1/GIP medicines.
- Review response, safety, adherence and contraception, not just weight.
- Know your local pathway, as access and prescribing responsibilities differ.
Discover more from The GP Pharmacy Club
Subscribe to get the latest posts sent to your email.